Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06583941 · ClinicalTrials.gov registry record · NA
Effects of Indena's Virtiva® Plus Ginkgo Biloba Extract on Stress, and Cognitive Performance
A NA study, sponsored by Applied Science & Performance Institute.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT06583941 is a NA study that has completed, run by Applied Science & Performance Institute. The registered enrollment target is 60 participants.
The verdict
NCT06583941, a NA study, has completed, sponsored by Applied Science & Performance Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, 5-week intervention clinical study that aims to investigate the dose-dependent effects of Virtiva® Plus on stress, and cognitive performance in participants experiencing heightened stress. The occurrence of adverse events in response to daily supplementation of Virtiva® Plus will also be measured. The desired sample size for this study is 24 subjects. To account for potential dropouts, we aim to enroll up to 20% over the desired sample size. Therefore, this study will enroll up to 29 subjects. Subjects will be randomly divided into two study groups: low dose (240 mg/day) or high dose (480 mg/day) of Virtiva® Plus. For both groups, the dose will be divided into two equal servings. Blocked randomization will be deployed in which subjects are divided into blocks of 2 subjects and each subject within a block is randomly assigned to one of the two study groups. Participants will be asked to stop taking alternative supplements used for cognitive enhancement 7 days prior to study related cognitive testing assessments.
Interventions
- DIETARY_SUPPLEMENT Low Dose Virtiva Plus
- DIETARY_SUPPLEMENT High Dose Virtiva Plus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-01-10 |
| Est. Completion | 2025-04-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06583941
The ClinicalTrials.gov registry entry for NCT06583941 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Applied Science & Performance Institute, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Low Dose Virtiva Plus is the first listed.
NCT06583941 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06583941 about?
NCT06583941 is a clinical study titled "Effects of Indena's Virtiva® Plus Ginkgo Biloba Extract on Stress, and Cognitive Performance". This is a randomized, double-blind, 5-week intervention clinical study that aims to investigate the dose-dependent effects of Virtiva® Plus on stress, and cognitive performance in participants experiencing heightened stress. The occurrence of adverse events in response to daily supplementation of Vi...
What is the current status of trial NCT06583941?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2025-01-10. Estimated completion is 2025-04-04.
What interventions are being tested in trial NCT06583941?
The interventions under investigation include: Low Dose Virtiva Plus (DIETARY_SUPPLEMENT), High Dose Virtiva Plus (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06583941?
This trial is sponsored by Applied Science & Performance Institute, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.